(Isonicotinic Acid Hydrazide, 4-Pyridinecarboxylic Acid Hydrazide)
Part B
Prices are indicative and are subject to change
White to off-white
Crystalline powder
Clear
Colourless
min. 99%
5.5 - 6.5
171 - 173°C
Antibiotic for treatment of Mycobacterium tuberculosis, inhibits mycolic acid biosynthesis. Metabolized by hepatic N-acetyltransferase (NAT) and cytochrome P450 2E1 (CYP2E1) to form hepatotoxins.
Selectively induces expression of CYP2E1. Reversibly inhibits CYP2C19 and CYP3A4 activities, and mechanistically inactivates CYP1A2, CYP2A6, CYP2C19 and CYP3A4 at clinically relevant concentrations.
Solubility (sparingly): acetone, acetonitrile, chloroform, ethanol, ethyl acetate, methanol, water
Insoluble : benzene, ether
8 to 25°C (Cool & Dry Area)
60 Months
Not Regulated for Transport (Non-Haz)
98020000 (GST 18%)
98020000 (GST 18%)
Glass Bottle
Plastic Bottle
